Vita Therapeutics
Cell engineering company that develops life-transformative treatments
Vita is progressing its lead program, VTA-100 for the treatment of limb-girdle muscular dystrophy (LGMD2A). Vita is developing this proprietary cellular therapies following a dual development strategy beginning with autologous-derived cells before moving to a universal hypoimmunogenic cell line.
We are a team of dedicated scientists striving to advance treatments in multiple indications within our cell therapy platform.
Vita Therapeutics was originally founded out of the labs of Dr. Gabsang Lee and Dr. Kathryn Wagner at Johns Hopkins University and the Kennedy Krieger Institute in 2019 by Douglas Falk, MS and Peter Andersen, PhD.
Vita Therapeutics Executive Team
• Douglas Falk, Chief Executive Officer and Co-Founder
• Peter Andersen, Co-Founder
Vita Therapeutics Board of Directors
• Douglas Falk
• Vlad Coric
• David Churchill
• Eva R. Chin
• James Peyer
• Mark Nuttall
Vita Therapeutics Scientific Advisory Board
• Lorenz Studer
• Sally Temple
• Mahendra Rao
• Stephen Chang
• Clifford Bechtold
• Paul Tesar
• Deok-Ho Kim
• Kapil Bharti
• David Sassoon
Visit website: https://www.vitatx.com/
Details last updated 16-Feb-2023
People at Vita Therapeutics
Vita Therapeutics News
Vita Therapeutics raised $31m to develop treatment for genetic diseases and cancers
Business Wire - 12-Oct-2022
Cell therapies aiming not only to correct the genetic defect but also repair and heal the muscle cells
Read more...